Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Global Medical REIT (GMRE-PB) EBITDA (2016 - 2025)

Global Medical REIT (GMRE-PB) has disclosed EBITDA for 10 consecutive years, with -$144.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA fell 335.82% year-over-year to -$144.1 million, compared with a TTM value of -$131.5 million through Dec 2025, up 16.84%, and an annual FY2025 reading of -$131.5 million, down 6.87% over the prior year.
  • EBITDA was -$144.1 million for Q4 2025 at Global Medical REIT, down from $41.8 million in the prior quarter.
  • Across five years, EBITDA topped out at $113.5 million in Q4 2023 and bottomed at -$144.1 million in Q4 2025.
  • Average EBITDA over 5 years is -$11.7 million, with a median of $4.9 million recorded in 2023.
  • The sharpest move saw EBITDA skyrocketed 466.24% in 2023, then plummeted 1935.1% in 2024.
  • Year by year, EBITDA stood at $8.9 million in 2021, then tumbled by 446.76% to -$31.0 million in 2022, then surged by 466.24% to $113.5 million in 2023, then crashed by 129.12% to -$33.1 million in 2024, then tumbled by 335.82% to -$144.1 million in 2025.
  • Business Quant data shows EBITDA for GMRE-PB at -$144.1 million in Q4 2025, $41.8 million in Q3 2025, and -$34.4 million in Q2 2025.